By: IPP Bureau
Last updated : May 27, 2025 8:34 am
Net profit for the?quarter came in at Rs. 2,889.1 crore, up 4.8 per cent from the year earlier, adjusted for exceptional items
Sun Pharmaceutical Industries Ltd has reported its Q4 results for the quarter and the full financial year ended 31st March, 2025.
The company’s consolidated gross sales for the quarter ended March 2025 was at Rs. 12,815.6 crore, reflecting 8.5 per cent YoY growth. During the quarter, India formulation sales rose by 13.6 per cent to Rs. 4,213 crore on the back of a strong prescription and an increasing portfolio of products in chronic therapies.
Net profit for the quarter came in at Rs. 2,889.1 crore, up 4.8 per cent from the year earlier, adjusted for exceptional items. However, reported net profit came in at Rs. 2,149.9 crore as against Rs. 2,654.6 crore in Q4 FY24 because of one-time charges.
The company’s R&D investment was at Rs. 816.6 crore. Operating performance was robust with EBITDA climbing 22.4 per cent to Rs. 3,716.1 crore. EBITDA margin for the quarter stood at 28.7 per cent.
For the full year FY25, Sun Pharma recorded gross sales of Rs. 52,041.2 crore, 9 per cent increase over FY24 driven more by consistent performance across all regions.
India formulation sales for the year were Rs. 16,923 crore, higher by 13.7 per cent, emerged as the key growth driver. The US segment achieved full-year sales of $1.921bn, an increase of 3.6 per cent, benefiting from a consistent platform of products.